

MRI in interstitial lung disease (M-ILD): a momentum to innovate lung diagnostic

Pierluigi Ciet  1,2

The prevalence of interstitial lung disease (ILD) is high and progressively increasing.¹ Mortality and morbidity vary according to ILD subtype, but overall median survival is poor, ranging from 5 to 14 years.² Irrespective of classification and cause of lung fibrosis, several patients present with progressive-fibrosing ILD (PF-ILD), characterised by a rapid decline in lung function.³

A recent landmark study demonstrated a reduction in PF-ILD disease progression using costly antifibrotic drugs.⁴ However, half of patients with ILD do not benefit from these expensive antifibrotic drugs but could be better treated with anti-inflammatory or combined treatment. Hence, there is an unmet need for a monitoring tool to phenotype patients with ILD by assessing the amount of pulmonary fibrosis and inflammation to guide treatment choices and monitor response.³

Current monitoring, namely, high-resolution CT (HRCT) and pulmonary function test, cannot differentiate between fibrotic lung disease and active inflammation.^{3,5} Histology can make this distinction, but biopsy is a high-risk procedure not routinely performed in patients with ILD. Conversely, chest MRI can offer a one-stop-shop solution for ILD providing structural and functional information in a single examination, such as ventilation inflammation perfusion and structure (VIPS-MRI).⁶ Using VIPS-MRI, both lung fibrosis and inflammation can be detected to select the best cost-effective treatment and to monitor its effect.⁷

In line with this concept, the interesting article published in this issue of *Thorax*, Weatherley and colleagues proposed a semiquantitative image measure of pulmonary perfusion based on the first pass of gadolinium-based contrast agent using dynamic contrast-enhanced MRI in a cohort of patients with PF-ILD. The study compares the full-width at half-maximum (FWHM_{mean}) of the dynamic

contrast curve averaged over the whole lung as an estimate of global pulmonary perfusion response to IPF and possible change in disease severity between baseline and a 6-month follow-up study. A second semiquantitative measure of the IQR of the distribution of FWHM values over the whole lung (FWHM IQR) is used as a candidate measure of pulmonary perfusion heterogeneity. The study presents promising and clinically relevant first results of pulmonary perfusion quantification as measure of disease progression and response to treatment in PF-ILD. New biomarkers are needed to evaluate progression of PF-ILD at earlier stages of disease.³ Previous studies on CT using quantitative methods, such as CALIPER, have clearly shown the close relationship between vascular pruning and progression of fibrosis.⁸ Quantification of pulmonary vasculature and perfusion are therefore strong predictors of patient outcome in PF-ILD.⁹ This strongly supports further development of MRI to assess pulmonary perfusion as a possible biomarker of early progression in PF-ILD.⁷ Despite the small cohort, the FWHM_{mean} shows reasonable repeatability, which is crucial for the selection of robust biomarkers, and that could be further improved by protocol refinement.

A few uncertainties remain. The use of a semiquantitative surrogate for pulmonary perfusion might be influenced by cardiac output, which in elderly population of PF-ILD can be quite variable, especially when another cardiac comorbidity is present. The biomarker proposed as measure of perfusion heterogeneity showed marginal repeatability, so FWHM_{mean} seems a better candidate as image biomarker. Finally, it is unclear if the difference measured using FWHM_{mean} between the two time points is related to progression of fibrosis rather than a reflection of true underlying vascular injury.

Said that, the study of Weatherley and colleagues can generate *new momentum to innovate lung diagnostic of PF-ILD*. It would be important to coordinate a joint effort for a multicentre study in an adequately selected group of patients with PF-ILD including measures of disease activity (eg, Krebs-von-den-Lungen 6, also known as KL-6), patient-reported outcome (eg, King's Brief Interstitial Lung Disease) and quantitative

HRCT biomarkers. Such validation will be crucial to introduce VIPS-MRI as a clinical tool for PF-ILD.

Acknowledgements P Wielopolski, MRI Physicist, Erasmus MC.

Collaborators Piotr Wielopolski, Radiology and Nuclear Medicine Department, Erasmus MC.

Contributors I've personally written the editorial.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Ciet P. *Thorax* 2021;**76**:108.

Accepted 16 November 2020

Published Online First 9 December 2020



- ▶ <http://dx.doi.org/10.1136/thoraxjnl-2020-214924>
- ▶ <http://dx.doi.org/10.1136/thoraxjnl-2019-214375>

Thorax 2021;**76**:108.

doi:10.1136/thoraxjnl-2020-216382

ORCID iD

Pierluigi Ciet <http://orcid.org/0000-0003-4017-8957>

REFERENCES

- 1 Olson AL, Gifford AH, Inase N, *et al*. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. *Eur Respir Rev* 2018;**27**:180077.
- 2 Kolb M, Vařáková M. The natural history of progressive fibrosing interstitial lung diseases. *Respir Res* 2019;**20**:57.
- 3 Cottin V, Wollin L, Fischer A, *et al*. Fibrosing interstitial lung diseases: knowns and unknowns. *Eur Respir Rev* 2019;**28**:180100.
- 4 Flaherty KR, Wells AU, Cottin V, *et al*. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med* 2019;**381**:1718–27.
- 5 Elicker BM, Kallianos KG, Henry TS. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. *Eur Respir Rev* 2017;**26**:170008.
- 6 Tiddens HAWM, Stick SM, Wild JM, *et al*. Respiratory tract exacerbations revisited: ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment. *Pediatr Pulmonol* 2015;**50**:S57–65.
- 7 Romei C, Turturici L, Tavanti L, *et al*. The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review. *Eur Respir Rev* 2018;**27**:180062.
- 8 Jacob J, Bartholmai BJ, Rajagopalan S, *et al*. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. *Eur Respir J* 2017;**49**:1601011.
- 9 Jacob J, Bartholmai BJ, Rajagopalan S, *et al*. Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. *Am J Respir Crit Care Med* 2018;**198**:767–76.

¹Radiology and Nuclear Medicine, Erasmus MC - Sophia Children's Hospital, Rotterdam, Zuid-Holland, Netherlands

²Pediatric Pulmonology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Zuid-Holland, Netherlands

Correspondence to MD, PhD Pierluigi Ciet, Radiology and Nuclear Medicine, Erasmus MC - Sophia Children's Hospital, Rotterdam, Zuid-Holland, Netherlands; p.ciet@erasmusmc.nl

